Toward a new treatment paradigm for hyperphosphatemia in chronic renal disease

Dialysis and Transplantation

Volumn 27, Issue 12, 1998, Pages 767-773

  Norris, Keith C ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; LANTHANUM CHLORIDE; MAGNESIUM HYDROXIDE; PHOSPHATE BINDING AGENT; PHOSPHORUS; POLYMER; SEVELAMER; UNCLASSIFIED DRUG; ZIRCONIUM DERIVATIVE;

CHRONIC KIDNEY DISEASE; DIET RESTRICTION; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; ORAL DRUG ADMINISTRATION; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW;

EID: 0032435397     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31:607-617.
2. Portale AA, Booth BE, Halloran BP, Morris RC Jr. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxy vitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73:1,580-589.
3. 2D. Kidney Int 1985; 27:565-573.
4. Hercz G, Coburn JW. Prevention of phosphate retention and hyperphosphatemia in uremia. Kidney Int 1987; 22(suppl):S215-S220.
5. Delmez JA, Slatopolsky E. Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303-317.
6. Norris KC, Crooks PW, Nebeker HG, et al. Clinical and laboratory features of aluminum-related bone disease: Differences between sporadic and "epidemic" forms of the syndrome. Am J Kidney Dis 1985; 6:342-347.
7. Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996; 45:111-119.
8. Ritz E, Hergesell O. Oral phosphate binders without aluminum and calcium: A pipe-dream? Nephrol Dial Transpl 1996; 11:766-768.
9. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991; 17:544-550.
10. 3): An efficient and safe phosphate binder in haemodialysis patients? A 3-year study. Nephrol Dial Transpl 1993; 8:530-534.
11. Curtin RB, Svarstad BL, Andress D, Keller T, Sacksteder P. Differences in older versus younger hemodialysis patients' noncompliance with oral medications. Geriatr Nephrol Urol 1997; 7:35-44.
12. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458-482.
13. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23:229-236.
14. Almaden Y, Canalejo A, Hernandez A, et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996; 11:970-976.
15. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994; 14:219-231.
16. Drucke TB. A clinical approach to the uraemic patient with extraskeletal calcifications. Nephrol Dial Transpl 1996; 11:37-42.
17. Gimenez LF, Solez K, Walker WG. Relation between renal calcium content and renal impairment in 246 human renal biopsies. Kidney Int 1987; 31:93-99.
18. Sanders C, Frank MS, Rostand SG, Rufsky EA, Barnes GT, Fraser RG. Metastatic calcification of the heart and lungs in end-stage renal disease: Detection and quantification by dual-energy digital chest radiography. Am J Roentgenol 1987; 149:881-887.
19. Rostand SG, Sanders C, Kirk KA, Rutsky EA, Fraser RG. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988; 85:651-657.
20. Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR. Aortic and mitral valve disease in patients with end-stage renal failure on long-term haemodialysis. Br Heart J 1992; 67:236-239.
21. Maher ER, Young G, Smyth-Walsh B, Pugh S, Curtis JR. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987; 2:875-877.
22. Huting J. Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. Chest 1994; 105:383-388.
23. Forman MB, Virmani R, Robertson RM, Stone WJ. Mitral annular calcification in chronic renal failure. Chest 1984; 85:367-371.
24. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27:394-401.
25. Massry SG. Divalent Ion Metabolism and Renal Osteodystrophy. In: Massry's and Glassock's Textbook of Nephrology (3rd Ed), Massry SG, Glassock RJ (eds). Baltimore: Williams & Wilkins, pp 1,441-1,473, 1995.
26. Llach F. Calcific uremic arteriolopathy (calciphylaxis): An evolving entity? Am J Kidney Dis 1998; 32:514-518.
27. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997; 29:641-649.
28. Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83:66-73.
29. Mai ML, Emmett M, Sheikh MS, Schiller L, Fordtran JS. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36:690-695.
30. Llach F, Yudd M. The importance of hyperphosphatemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transpl 1998; 13:57-61.
31. Oe PL, Lips P, van der Meulen J, de Vries PM, van Bronswijk H, Donker AJ. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 1987; 28:180-185.
32. Breuer J, Moniz C, Baldwin D, Parsons V. The effects of zero magnesium dialysate and magnesium supplements on ionized calcium concentration in patients on regular dialysis treatment. Nephrol Dial Transpl 1987; 2:347-350.
33. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binden A prospective, controlled, crossover study. Kidney Int 1996; 49:163-167.
34. Sherrard DJ. Renal Osteodystrophy. In: Principles and Practice of Dialysis, Henrich WL (ed.). Baltimore: Williams & Wilkins, pp 234-245, 1994.
35. Wallot M, Bonzel KE, Winter A, Georger B, Lettgen B, Bald M. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 1996; 10:625-630.
36. Argiles i Ciscart A. Points to remember when selecting dialysate calcium concentration. Nephrol Dial Transpl 1995; 10:451-454.
37. Fernandez E, Borras M, Pais B, Montoliu J. Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism. J Am Soc Nephrol 1995; 6:132-135.
38. Piraino B, Bernardini J, Holley JL, Perlmutter JA. Increased risk of Staphylococcus epidermidis peritonitis in patients on dialysate containing 1.25 mmol/L calcium. Am J Kidney Dis 1992; 19:371-374.
39. Norris KC. Determining the appropriate dosage of Calcijex (calcitriol injection) for hemodialysis patients with secondary hyperparathyroidism. Neph Exchange 1996; 6:5-11.
40. Renaud H, Atik A, Herve M, et al. Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: Lack of influence of calcium carbonate. Nephron 1988; 48:28-32.
41. 3. Nephrol Dial Transpl 1989; 4:1045-1053.
42. 3: An inefficient and unsafe phosphate binder? Nephrol Dial Transpl 1994; 9:335-336.
43. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): A non-calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29:66-71.
44. Burke SK, Slatopolsky E, Goldberg DI. RenaGel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transpl 1997; 12:1,640-644.
45. Graff L, Burnel D. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption. Res Commun Mol Pathol Pharmacol 1995; 89:373-388.
46. Graff L, Burnel D. Reduction of dietary phosphorus absorption by oral phosphorus binders. Res Commun Mol Pathol Pharmacol 1995; 90:389-401.